The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from Marketwire

MethylGene to Present MGCD265 Data at the 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Wednesday, October 31, 2012

MethylGene to Present MGCD265 Data at the 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics09:00 EDT Wednesday, October 31, 2012MONTREAL, CANADA--(Marketwire - Oct. 31, 2012) - MethylGene Inc. (TSX:MYG) today announced that preclinical data for its clinical-stage Met/VEGFR inhibitor MGCD265, will be presented at the 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, taking place in Dublin, Ireland from November 6 to 9, 2012. This poster presentation will describe the use of a novel ex vivo assay to measure the inhibition of Met activity by MGCD265 using patient plasma samples.Poster PresentationA Novel Assay for the Met Inhibitory Activity of MGCD265 in Plasma From Solid Tumor Patients in a Dose Escalating Phase I StudyDate and Time:Thursday November 8, 2012, 12:00 PM to 2:15 PM (GMT)Session:Met, Ret and Notch Presentation No.:062 (abstract 312)Location:ForumAbout MethylGeneMethylGene Inc. (TSX:MYG) is a drug development company that is advancing novel therapeutics for cancer and infectious disease in human clinical trials. The Company's lead product candidates are: MGCD290, an oral antifungal agent targeting the fungal Hos2 enzyme that is in Phase II trials for vulvovaginal candidiasis, and MGCD265, an oral Met/VEGF receptor kinase inhibitor that is in Phase I/II clinical trials for patients with solid tumors. MethylGene owns all rights to its lead product candidates, and has partnerships with Otsuka Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd., and EnVivo Pharmaceuticals, Inc. for its other pipeline programs.Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Such statements, based as they are on the current expectations of management of MethylGene, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond MethylGene's control. These risks and uncertainties could cause future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Such results, performance or achievements include, but are not limited to, the timing and effects of regulatory action; the continuation of collaborations; the results of clinical trials; the timing of enrollment or completion of clinical trials; the success, efficacy or safety of MGCD265, MGCD290 or our other programs; the ability to scale up, formulate and manufacture sufficient GMP, clinical or commercialization quantities of MGCD265, MGCD290 or our other products, and the relative success or the lack of success in developing and gaining regulatory approval and/or market acceptance for any compound or new product including MGCD265 or MGCD290. Such risks include, but are not limited to, the impact of general economic conditions, economic conditions in the pharmaceutical industry, changes in the regulatory environment in the jurisdictions in which MethylGene does business, stock market volatility, fluctuations in costs, expectations with respect to our intellectual property position and our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others, changes in the competitive landscape including changes in the standard of care for the various indications in which MethylGene is involved, and changes to the competitive environment due to consolidation, as well as other risks, as described in MethylGene's Annual Information Form under the heading "Risk Factors" which you are urged to read, and all other documents filed by the Company that can be found at www.sedar.com. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. The reader should not place undue reliance on the forward-looking statements included in this news release. These statements speak only as of the date they are made and MethylGene expressly disclaims any duty, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in MethylGene's expectations with regard thereto of any change in events, conditions or circumstances on which any such statements are based except in accordance with law.FOR FURTHER INFORMATION PLEASE CONTACT: Contact Information: Joseph Walewicz, CFAVice President, Business & Corporate DevelopmentMethylGene Inc.Phone: 514-337-3333 ext. 373ir@methylgene.comwww.methylgene.comThomas HoffmannVice PresidentThe Trout Group LLCPhone: 646-378-2931thoffmann@troutgroup.comwww.troutgroup.com